Rescue cat’s legacy funds long-term feline heart research: full analysis
A rescue cat named Vladimir, adopted after being labeled dangerous by a shelter, has become the inspiration for a new permanent research investment in feline cardiology at NC State. In April 2026, the college announced the Vladimir Cader Feline Health Research Distinguished Chair, endowed by Amos Cader after Vladimir’s death from hypertrophic cardiomyopathy in 2024, with Dr. Joshua Stern named as the first recipient. (cvm.ncsu.edu)
The announcement builds on a relationship that began when Cader contacted Stern about his rapamycin research in cats with HCM. According to NC State, those conversations led first to direct research support, then to the Vladimir Cader Early Innovator in Feline Research Award, and now to an endowed chair intended to fund feline health research in perpetuity. NC State’s Board of Trustees materials list the Vladimir Cader Feline Health Research Distinguished Chair among professorships established in fiscal year 2025, adding a regulatory and institutional paper trail behind the college’s announcement. (cvm.ncsu.edu)
The scientific backdrop is important. HCM is the most common heart disease in cats, and NC State says about 15% of cats are affected. The college has a long-running interest in feline cardiac genetics, including ongoing recruitment for a Sphynx HCM genetics study aimed at identifying disease-associated mutations. More broadly, feline HCM has drawn research attention not just because of its prevalence in practice, but because it also serves as a spontaneous large-animal model with translational relevance to human cardiomyopathy. (cvm.ncsu.edu)
That context helps explain why Vladimir’s story has landed beyond donor news. Stern is a recognized figure in feline cardiology research and received the American Veterinary Medical Foundation’s 2024 Career Achievement in Feline Research Award. NC State says his lab’s work contributed to development of sirolimus therapy for feline HCM, and the FDA announced in March 2025 that it had conditionally approved Felycin-CA1 for management of ventricular hypertrophy in cats with subclinical HCM, the first approved drug for that indication in cats. Under FDA rules, conditional approval can allow legal marketing for up to five years while the sponsor gathers the remaining effectiveness data for full approval. (news.cvm.ncsu.edu)
NC State is also tying the new chair to the clinical trial pipeline already underway. In the university’s announcement, Stern said the HALT study had enrolled more than 300 cats across 28 academic and private-practice centers and described it as the largest feline cardiology clinical trial to date, with completion expected in 2027. The HALT study site confirms multicenter recruitment, reinforcing that this is not a single-institution effort but a networked study that depends on referral practices and specialty cardiology participation. (cvm.ncsu.edu)
Industry and institutional reaction has centered on scale and durability. Stern called the gift “transformational” because the endowment will generate annual funds to support research over time, and NC State framed the chair as a platform to keep advancing feline heart disease work beyond any single project cycle. That matters in feline medicine, where investigators and donors alike have often pointed to a thinner research funding base than exists in some other companion-animal categories. (cvm.ncsu.edu)
Why it matters: For veterinary professionals, the bigger story is that philanthropic capital is helping build the infrastructure around feline specialty research, not just funding one-off studies. An endowed chair, trainee awards, and fellowship support can strengthen the pipeline from genetics and biomarker discovery to multicenter trials and, potentially, practice-changing therapeutics. For clinicians counseling pet parents about HCM risk, especially in predisposed breeds such as Sphynx cats, this kind of investment could gradually improve screening, prognostication, and treatment options, even if the current drug landscape remains limited and still partly conditional. (cvm.ncsu.edu)
What to watch: The next markers will be whether the HALT study stays on pace for a 2027 finish, whether peer-reviewed results further clarify sirolimus’ clinical benefit in subclinical HCM, and how NC State uses the new chair to expand feline cardiology training, recruitment, and translational research capacity. (cvm.ncsu.edu)